Valeant Pharmaceuticals Intl 

“Market Cap $44.62 B As of May 2014

At a Glance

  • Industry: Pharmaceuticals
  • Founded: 1983
  • Country: Canada
  • CEO: J Michael Pearson
  • Website: www.valeant.com
  • Employees: 17,200
  • Sales: $5.79 B
  • Headquarters: Laval

Forbes Lists

#921 Global 2000

  • #1505 in Sales
  • #798 in Assets
  • #224 in Market value

#62 Innovative Companies


Valeant Pharmaceuticals International, Inc. is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, eye health, neurology, and branded generics. The company was founded on March 29, 1994 and is headquartered in Laval, Canada.

“Valeant Pharmaceuticals Intl History

Valeant was founded as a United States business. It has undergone major management, operational and strategic restructurings since the 1990s when shareholders of several group units approved the merger of ICN Pharmaceuticals (founded by Milan Panić), ICN Biomedicals, SPI Pharmaceuticals and Viratek into a new global entity, ICN Pharmaceuticals, the immediate forebear of Valeant.

In 2008 the Swedish pharmaceutical company Meda AB bought branches in Western and Eastern Europe from Valeant Pharmaceuticals for $392 Million.”

*Information from Forbes.com and Wikipedia.org

**Video published on YouTube by “LifeScienceMB